Menu

Home / Guides / Trulicity vs. tirzepatide

Two weekly shots, both from Lilly.

Trulicity vs. Tirzepatide (2026): Stay on Trulicity or Switch to Mounjaro?

By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD (NPI 1144260043) · Updated

Head to head, Mounjaro (tirzepatide) lowered A1c and weight more than Trulicity (SURPASS J-mono, 2022) and wasn’t worse on heart events (SURPASS-CVOT, 2025). Both are type 2 diabetes medicines, off-label for weight loss; Zepbound, also tirzepatide, is approved for it. NexLife’s providers prescribe compounded tirzepatide, which isn’t FDA-approved, for weight loss, not type 2 diabetes: $115 a month on the 12-month plan, or $129 month to month.

  • Since August 2026: Mounjaro, like Trulicity, has a heart-risk use
  • Trulicity’s savings card: ends December 31, 2026
  • Medicare: any negotiated Trulicity price starts January 1, 2028
Published by NexLifeLegitScript-certified
NexLifeSame price at every dose
Illustration of a compounded tirzepatide vial

$115/mo on a 12-month plan, all-inclusive, same price at every dose

Or $129/mo month to month

Brand-name Zepbound, for weight: $299 to $449 a month at LillyDirect, by dose; $449 (from 7.5 mg) needs a refill within 45 days, or it’s $499 to $699

Check my eligibility

About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication

See all 4 plans and what a year costs
Compounded tirzepatide, all in, the same price at every dose
PlanPer month12 months at this rate
12-month Most savings$115$1,380
6-month$119$1,428
3-month$125$1,500
Month to month$129$1,548

Month to month costs $168 more over 12 months than the 12-month plan. Month to month is billed monthly; the 3-, 6- and 12-month plans are paid upfront at checkout: $375, $714 or $1,380. Plans renew until you cancel.

Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026)LegitScript-certified

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.

  • Licensed U.S. providers
  • LegitScript certified
  • Free expedited shipping
  • HSA, FSA, Affirm, Klarna, Afterpay
  • 24/7 support, real people
  • Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)

These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied. It isn’t FDA-approved or Mounjaro, and a licensed provider prescribes it only when it offers a significant difference for you.

In short

Trulicity vs. Mounjaro (tirzepatide): how do they compare?

Two trials compared them head to head. Here’s what they found, and what each costs.

Trulicity vs. tirzepatide, in short, from the sections below: the Trulicity and Mounjaro labels, SURPASS J-mono (2022), SURPASS-CVOT (2025) and LillyDirect, checked November 1, 2026. These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.
QuestionAnswer
How do they work?Trulicity (dulaglutide) acts on GLP-1; tirzepatide (Mounjaro) acts on GIP and GLP-1. Both are weekly Lilly shots.
Which lowered A1c more?Tirzepatide: 2.4% to 2.8% vs. 1.3% on Trulicity 0.75 mg over 52 weeks (SURPASS J-mono, 2022).
Which lowered weight more?Tirzepatide: 5.8 to 10.7 kg vs. 0.5 kg on Trulicity 0.75 mg, in the same trial.
Heart events?Tirzepatide was non-inferior to Trulicity 1.5 mg (hazard ratio 0.92): not worse, not shown to be better (SURPASS-CVOT, 2025).
For weight loss?Neither is FDA-approved for it; both treat type 2 diabetes. Zepbound, also tirzepatide, is approved for weight loss.
Self-pay price?Mounjaro: $499 a month at LillyDirect (checked November 15, 2026). Lilly’s Trulicity savings page lists no self-pay price.

These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.

  1. Tell us about you About 3 minutes of health questions
  2. A licensed provider decides You’re prescribed only if it’s right for you
  3. Your partner pharmacy ships Usually within 1 to 2 business days, free

Key takeaways

  • Head to head, tirzepatide lowered A1c more: 2.4% to 2.8% vs. 1.3% on Trulicity 0.75 mg (SURPASS J-mono, 2022).
  • Weight fell more too, on average: 5.8 to 10.7 kg on tirzepatide vs. 0.5 kg on Trulicity 0.75 mg (SURPASS J-mono, 2022).
  • Both labels now include heart-risk reduction. In SURPASS-CVOT (2025), tirzepatide was no worse than Trulicity 1.5 mg, not shown to be better.
  • Both are type 2 diabetes medicines. For weight loss they’re off-label; Zepbound, also tirzepatide, is approved for it.
  • Two cost dates: Trulicity’s savings card ends December 31, 2026; any Medicare-negotiated Trulicity price starts January 1, 2028.
  • At NexLife, compounded tirzepatide is $115 a month on the 12-month plan, for weight loss. It isn’t FDA-approved or a diabetes treatment.

At a glance

How are Trulicity and tirzepatide different?

Both are weekly Lilly shots for type 2 diabetes, with the same boxed warning, but tirzepatide acts on two hormone receptors and goes to a higher dose; Trulicity acts on one. Head to head, tirzepatide lowered A1c more: 2.4% to 2.8% vs. 1.3% on Trulicity 0.75 mg (SURPASS J-mono, 2022).

Sources: the Trulicity label (revised March 2026), the Mounjaro label (revised August 2026), the SURPASS J-mono paper, Lilly’s savings terms and its January 2025 Trulicity price disclosure, LillyDirect, Medicare.gov and CMS, checked November 1, 2026. These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.
Trulicity (dulaglutide)Tirzepatide (Mounjaro)
Who makes itEli LillyEli Lilly
What it acts onOne hormone receptor: GLP-1Two hormone receptors: GIP and GLP-1
FDA-approved forBlood sugar control in adults and children 10 and older with type 2 diabetes. Lowering the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes and established cardiovascular disease or several cardiovascular risk factorsBlood sugar control in adults and children 10 and older with type 2 diabetes. Since August 2026, lowering the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes at high risk
Weight lossNot FDA-approved: off-labelNot FDA-approved as Mounjaro: off-label. Zepbound, also tirzepatide, is approved for it
How you take itOne shot a week, from a single-dose penOne shot a week: a single-dose pen or vial, a four-dose KwikPen or a multi-dose vial
Doselabel range0.75 mg to start, 1.5 mg after 4 weeks, then 1.5 mg steps at least 4 weeks apart, up to 4.5 mg. Children: up to 1.5 mg2.5 mg to start, then 2.5 mg steps at least 4 weeks apart, up to 15 mg. Children: up to 10 mg
Blood sugar, head to headSURPASS J-mono, 2022A1c down 1.3% on 0.75 mg over 52 weeksA1c down 2.4% to 2.8% on 5 to 15 mg
Heart events, head to headSURPASS-CVOT, 2025The comparison: Trulicity 1.5 mgNon-inferior to Trulicity 1.5 mg (hazard ratio 0.92); superiority not shown
Most common side effectslabel, vs. placeboNausea in 12.4% to 21.1% (5.3% on placebo), diarrhea, vomiting, stomach painNausea in 12% to 18% (4% on placebo), diarrhea, less appetite, vomiting
Boxed warningThyroid C-cell tumors in rats. Don’t use it with a personal or family history of MTC, or with MEN 2Thyroid C-cell tumors in rats. Don’t use it with a personal or family history of MTC, or with MEN 2
Self-pay price, a monthchecked November 1, 2026None on Lilly’s Trulicity savings page. List price: $987.19 for four pens (Lilly, January 2025)$499 at LillyDirect, at every dose
Savings cardcommercial insurance that covers itAs little as $25 for up to 3 months, up to $1,950 a year. Ends December 31, 2026As little as $25 for up to 3 months
Medicare, 2026 to 2028Part D should cover it for type 2 diabetes. On Medicare’s 2028 negotiation list: any agreed price starts January 1, 2028Part D should cover it for type 2 diabetes. Not on the 2028 negotiation list

Sources: the Trulicity label (revised March 2026), the Mounjaro label (revised August 2026), the SURPASS J-mono paper, Lilly’s savings terms and its January 2025 Trulicity price disclosure, LillyDirect, Medicare.gov and CMS, checked November 1, 2026. These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.

How they work. Trulicity is a GLP-1 receptor agonist, its label says. Tirzepatide acts on both the GIP and GLP-1 receptors; its label puts its half-life at about 5 days, “enabling once-weekly dosing.” Both are pens you use once a week; Mounjaro also comes in vials.

Which fits you

Trulicity or tirzepatide: which fits your situation?

Your provider decides with you. These label and trial facts usually shape the choice.

  • If Trulicity is working for you

    No label says you should switch. Before January, ask what your plan will charge: Trulicity’s savings card expires December 31, 2026. What else changes: GLP-1 coverage in 2027.

  • If your A1c or weight isn’t where you want it

    Head to head, tirzepatide lowered both more than Trulicity 0.75 mg (SURPASS J-mono, 2022). Trulicity also goes up to 4.5 mg, which lowered A1c a little more than 1.5 mg did (AWARD-11, 2021).

  • If heart protection is the priority

    Both labels now include lowering the risk of heart attack, stroke and heart-related death. In SURPASS-CVOT (2025), tirzepatide was non-inferior to Trulicity 1.5 mg: not worse, and not shown to be better.

  • If your child, 10 to 17, has type 2 diabetes

    Both are approved from age 10 for type 2 diabetes. In children, Trulicity goes up to 1.5 mg a week and Mounjaro up to 10 mg.

  • If you have Medicare

    Your Part D plan should cover a GLP-1 for type 2 diabetes, Medicare.gov says. Lilly’s savings cards don’t work with Medicare, and the GLP-1 Bridge isn’t open to people with type 2 diabetes.

  • If weight loss is the main goal

    Neither Trulicity nor Mounjaro is FDA-approved for weight loss; using either for it is off-label. Zepbound, also tirzepatide, is: tirzepatide for weight loss.

Head to head

Is tirzepatide better than Trulicity?

For blood sugar and weight, yes: tirzepatide lowered A1c by 2.4% to 2.8% vs. 1.3% and weight by 5.8 to 10.7 kg vs. 0.5 kg on Trulicity 0.75 mg (SURPASS J-mono, 2022). For heart events, it was non-inferior to Trulicity 1.5 mg: not worse, but not shown to be better.

SURPASS J-mono from its published paper; SURPASS-CVOT from the Mounjaro label; both read November 15, 2026. These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.
SURPASS J-mono (2022)SURPASS-CVOT (2025)
What it measuredBlood sugar (A1c) and weightHeart attack, stroke or heart-related death
PublishedThe Lancet Diabetes & Endocrinology, 2022The New England Journal of Medicine, 2025 (results as on Mounjaro’s label)
Who took part636 Japanese adults with type 2 diabetes, taking no other diabetes medicine13,299 adults with type 2 diabetes and established cardiovascular disease; average age 64, A1c 8.4%
ComparedTirzepatide 5, 10 or 15 mg vs. Trulicity 0.75 mgTirzepatide up to 15 mg vs. Trulicity 1.5 mg
Length52 weeksMedian follow-up 210 weeks, about 4 years
Main resultA1c −2.4% to −2.8% vs. −1.3% on TrulicityHazard ratio 0.92 95.3% CI 0.83 to 1.01: non-inferior; superiority not shown
Body weight−5.8 kg to −10.7 kg on tirzepatide, vs. −0.5 kg on TrulicityNot on the label

Swipe the table sideways to see every column.

SURPASS J-mono from its published paper; SURPASS-CVOT from the Mounjaro label; both read November 15, 2026. These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.

Read the fine print. SURPASS J-mono compared tirzepatide with Trulicity’s 0.75 mg starting dose, in Japanese adults on no other diabetes medicine. In the U.S., Trulicity goes up to 4.5 mg.

Trulicity’s higher doses. In AWARD-11 (Diabetes Care, 2021), 1,842 adults on metformin took 1.5, 3 or 4.5 mg. After 36 weeks, A1c fell 1.5%, 1.6% and 1.8%, and weight fell 3.0, 3.8 and 4.6 kg, Trulicity’s label reports.

Trulicity’s own heart trial. In REWIND (The Lancet, 2019), 9,901 adults with type 2 diabetes took Trulicity 1.5 mg or placebo for a median 5.4 years. The risk of heart attack, stroke or heart-related death was 12% lower on Trulicity (hazard ratio 0.88). About a third had established cardiovascular disease.

Weight

Trulicity vs. Mounjaro for weight loss: which works better?

Tirzepatide, in trials: in people with type 2 diabetes, weight fell 5.8 to 10.7 kg on tirzepatide vs. 0.5 kg on Trulicity 0.75 mg (SURPASS J-mono, 2022). Neither Trulicity nor Mounjaro is FDA-approved for weight loss, so using either for it is off-label; Zepbound, also tirzepatide, is approved for it.

From the SURPASS J-mono paper, the Trulicity label (AWARD-11) and SURMOUNT-2 (the Zepbound label’s Study 2), read November 1, 2026. These trials studied FDA-approved Zepbound, Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.
TrialTrulicityTirzepatide
SURPASS J-mono (2022)52 weeks, head to head−0.5 kg on 0.75 mg−5.8 kg on 5 mg to −10.7 kg on 15 mg
AWARD-11 (2021)36 weeks, Trulicity doses only−3.0 kg on 1.5 mg, −3.8 kg on 3 mg, −4.6 kg on 4.5 mgNot studied
SURMOUNT-2 (2023)72 weeks, type 2 diabetes, vs. placebo (Study 2 on Zepbound’s label)Not studied14.7% of body weight on 15 mg and 12.8% on 10 mg, vs. 3.2% on placebo

Swipe the table sideways to see every column.

From the SURPASS J-mono paper, the Trulicity label (AWARD-11) and SURMOUNT-2 (the Zepbound label’s Study 2), read November 1, 2026. These trials studied FDA-approved Zepbound, Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.

Trulicity vs. Zepbound. If weight is the main goal, Zepbound is the tirzepatide brand approved for it, in adults with obesity, or overweight with a weight-related condition. It’s $299 to $449 a month at LillyDirect, by dose; $449 (from 7.5 mg) needs a refill within 45 days, or it’s $499 to $699. More: Zepbound cost without insurance.

“to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.”

Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, section 1, what Zepbound is approved for (revised August 2026)

Side effects

How do Trulicity’s and Mounjaro’s side effects compare?

Both mostly cause stomach side effects, more often at higher doses. Head to head, nausea and loss of appetite were more common on tirzepatide than on Trulicity 0.75 mg. Their labels warn about nearly the same things and carry the same boxed warning about thyroid tumors in rats.

From each label’s placebo-controlled trials: Trulicity 0.75 and 1.5 mg, Mounjaro 5 to 15 mg. Not head-to-head. Read November 1, 2026. These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.
Side effectTrulicity (label, vs. placebo)Mounjaro (label, vs. placebo)
Nausea12.4% on 0.75 mg, 21.1% on 1.5 mg (placebo 5.3%)12% on 5 mg to 18% on 15 mg (placebo 4%)
Diarrhea8.9% to 12.6% (placebo 6.7%)12% to 17% (placebo 9%)
Vomiting6.0% to 12.7% (placebo 2.3%)5% to 9% (placebo 2%)
Less appetite4.9% to 8.6% (placebo 1.6%)5% to 11% (placebo 1%)
Stomach pain6.5% to 9.4% (placebo 4.9%)5% to 6% (placebo 4%)
Stopped for stomach side effects1.3% to 3.5% (placebo 0.2%)3.0% to 6.6% (placebo 0.4%)

Swipe the table sideways to see every column.

From each label’s placebo-controlled trials: Trulicity 0.75 and 1.5 mg, Mounjaro 5 to 15 mg. Not head-to-head. Read November 1, 2026. These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.

Head to head (SURPASS J-mono, 2022, 52 weeks), nausea hit 12% to 20% on tirzepatide vs. 8% on Trulicity 0.75 mg. Loss of appetite hit 13% to 22% vs. 4%. On Trulicity 3 mg and 4.5 mg, nausea was 15.6% and 16.4%, vs. 13.4% on 1.5 mg (AWARD-11, 2021).

Tips for stomach side effects, and when to call: tirzepatide side effects.

Switching

How do you switch from Trulicity to Mounjaro?

With your provider, who sets the timing. The Mounjaro label starts everyone at 2.5 mg a week and goes to 5 mg after 4 weeks; higher doses come only if blood sugar needs more control. Don’t take it with Trulicity: both act on GLP-1.

  1. Talk to your provider first

    They’ll weigh why you’re switching: your A1c, your weight, side effects, cost or your heart risk. Then they decide when your last Trulicity dose is and when tirzepatide starts.

  2. Don’t double up

    Both act on GLP-1. The Zepbound label, also tirzepatide, says not to combine tirzepatide with any GLP-1 medicine.

  3. Start at the label’s first step

    Mounjaro starts at 2.5 mg a week, a starting dose only, and goes to 5 mg after 4 weeks. If blood sugar needs more control, it then goes up in 2.5 mg steps at least 4 weeks apart, to as much as 15 mg. Your provider sets your own plan.

  4. Check insulin and sulfonylureas

    Both labels warn of low blood sugar when used with insulin or a sulfonylurea. A lower dose of those can lower that risk, both labels say.

  5. Plan for birth control pills

    Mounjaro can make birth control pills work less well. Its label says to switch to a non-oral method, or add a barrier method, for 4 weeks after you start and after each dose increase.

“ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”

Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, section 1, Limitations of Use (revised August 2026)

Compounded tirzepatide isn’t a substitute. NexLife’s providers prescribe it for weight loss, not to treat type 2 diabetes, and it doesn’t replace Trulicity or Mounjaro. If you’re thinking about it for weight, talk with the doctor who manages your diabetes. List every medicine you take in the online assessment; a licensed provider decides whether it’s right for you. Our Price Match Guarantee† covers only compounded tirzepatide or semaglutide from another provider.

Safety

What do the Trulicity and Mounjaro labels warn about?

The Trulicity and Mounjaro labels warn about nearly the same things, and carry the same boxed warning about thyroid tumors in rats.

Don’t take either if

  • You or a family member has had medullary thyroid carcinoma (MTC), or you have MEN 2, an inherited gland condition. That’s the boxed warning: both caused thyroid C-cell tumors in rats, and it isn’t known whether they do in people.
  • You’ve had a serious allergic reaction to the medicine or anything in it.

Warnings on both labels

Pancreatitis; low blood sugar with insulin or a sulfonylurea; serious allergic reactions; kidney injury from dehydration; severe stomach side effects; diabetic retinopathy complications in people who already have retinopathy; gallbladder disease; and food in the lungs under anesthesia or deep sedation. Both labels also say they aren’t recommended with severe gastroparesis. Mounjaro’s label adds: never share a KwikPen. Both medicines slow stomach emptying, so they can slow how fast pills you take are absorbed.

Call your provider right away about

  • A lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath
  • Severe stomach pain that could be pancreatitis: the labels say to stop the medicine if pancreatitis is suspected
  • A pregnancy, or plans for one: both labels say to use them in pregnancy only if the benefit justifies the risk to the baby

A question about a side effect? We answer 24/7 at (949) 818-8000, by call or text.

Cost

How much do Trulicity and Mounjaro cost, with or without insurance?

With commercial insurance that covers them, Lilly’s savings cards bring either to as little as $25 for up to 3 months; Trulicity’s savings card ends December 31, 2026. Paying yourself, Mounjaro is $499 a month at LillyDirect (checked November 15, 2026). Lilly lists no self-pay price on its Trulicity savings page; Trulicity’s list price was $987.19 for four pens in January 2025.

Lilly’s savings terms, LillyDirect, Medicare.gov and CMS checked November 1, 2026; a LillyDirect month is 28 days, so a year is 13 fills. Trulicity’s list price: Lilly’s state price disclosures, priced as of January 2, 2025. Compounded prices: our GLP-1 price index, all in, month to month, checked November 1, 2026. Compounded tirzepatide isn’t Mounjaro, and the FDA hasn’t approved it.
How you payWhat it costsGood to know
Trulicity savings cardcommercial insurance that covers itAs little as $25 for up to a 3-month fillUp to $150 off a month and $1,950 a year. Ends December 31, 2026. Not for Medicare or other government plans
Mounjaro savings cardcommercial insurance that covers itAs little as $25 for up to a 3-month fill (84 days, up to 12 pens)Not for Medicare or other government plans
Mounjaro, LillyDirect self-paysingle-dose pens$499 a monthAt every dose, four pens a fill. A year of 13 fills is $6,487
Trulicity, paying yourselfNo self-pay price on Lilly’s Trulicity savings pageYour pharmacy sets the cash price
Trulicity list pricewhat Lilly charges wholesalers$987.19 for four pensLilly’s January 2025 price disclosure, the latest we could read. Before any discount, and not a pharmacy price
Medicare Part Dtype 2 diabetesYour plan’s copay or coinsurancePlans should cover a GLP-1 for type 2 diabetes, Medicare.gov says. The GLP-1 Bridge isn’t open to people with type 2 diabetes
Medicare price negotiationTrulicity: selected for 2028CMS publishes any agreed price by November 30, 2026; it takes effect January 1, 2028. Medicare spent $4.9 billion on Trulicity from November 2024 to October 2025, for 617,000 people. Mounjaro isn’t on the 2028 list
Zepbound, LillyDirect self-paytirzepatide for weight loss$299 to $449 a month, by dose$449 (from 7.5 mg) needs a refill within 45 days, or it’s $499 to $699. FDA-approved for weight loss, including in adults with type 2 diabetes, but not to treat diabetes
Compounded tirzepatide online25 programs with a month-to-month price, for weight loss; not FDA-approved, not a diabetes treatment$126 to $599 a month in our price index, month to month (median $285)Checked Nov. 15, 2026. Paying less elsewhere? Our Price Match Guarantee† matches your regular monthly price
NexLife, 12-month planfor weight loss; not FDA-approved, not a diabetes treatment$115 a month$1,380 a year, at every dose
NexLife, month to monthfor weight loss; not FDA-approved, not a diabetes treatment$129 a month$1,548 a year, at every dose

NexLife Price Match Guarantee†. Already on compounded tirzepatide with another licensed provider, and paying less? We match your regular monthly price. How it works

Swipe the table sideways to see every column.

Lilly’s savings terms, LillyDirect, Medicare.gov and CMS checked November 1, 2026; a LillyDirect month is 28 days, so a year is 13 fills. Trulicity’s list price: Lilly’s state price disclosures, priced as of January 2, 2025. Compounded prices: our GLP-1 price index, all in, month to month, checked November 1, 2026. Compounded tirzepatide isn’t Mounjaro, and the FDA hasn’t approved it.

The yearly math. Paying yourself, Mounjaro at $499 a fill is $6,487 for 13 fills. If insurance covers Mounjaro or Trulicity for your diabetes, that usually costs far less. Compounded tirzepatide is a different product: it isn’t FDA-approved, isn’t Mounjaro and wasn’t studied in Mounjaro’s trials. NexLife’s providers prescribe compounded tirzepatide for weight loss. It isn’t a treatment for type 2 diabetes and doesn’t replace Trulicity, Mounjaro or your diabetes care.

“However, compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.”

U.S. Food and Drug Administration, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Price Match Guarantee†: for compounded tirzepatide or semaglutide from another licensed U.S. telehealth provider or clinic, not brand-name medicines, and not for people with Medicare, Medicaid or TRICARE. How it works.

At NexLife

What does NexLife offer if you’re weighing tirzepatide?

Compounded tirzepatide at one monthly price, a licensed provider who decides if it’s right for you, and care that comes with it.

  • One price at every dose

    $115 a month on the 12-month plan, $119 on 6 months, $125 on 3 months or $129 month to month, from 2.5 mg to 15 mg. No membership fee. Month to month, $129 is $156 under the $285 median of the 25 programs with a month-to-month price in our GLP-1 price index (checked Nov. 15, 2026).

  • A licensed provider decides

    They review your health history and every medicine you take, and prescribe only if treatment is right for you. Our medical director is Adam Kennah, MD, board-certified in emergency medicine (ABEM). Not prescribed? No charge for medication.

  • Two named pharmacies

    Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA), both state-licensed 503A partner pharmacies, fill your prescription. Expedited shipping is free, and questions come to us.

  • Care between refills

    A nutrition plan, a 1:1 coaching call and real people 24/7 at (949) 818-8000. Pay with Affirm, Klarna, Afterpay, or an HSA or FSA card; NexLife provides a letter of medical necessity.

  • Checked and rated

    LegitScript-certified, and rated 4.8 out of 5 on Trustpilot from 407 reviews (read November 15, 2026). Paying less for compounded tirzepatide elsewhere? Our Price Match Guarantee† matches your regular monthly price.

  • What happens next

    A 3-minute online assessment, a licensed provider’s review, then your pharmacy ships. With Medicare, you can pay for yourself.

Vial math

How many units is your tirzepatide dose?

Your tirzepatide dose in units depends on your vial’s strength. Here are the label’s doses at one example strength, with the math to check your own.

Tirzepatide doses on Zepbound’s label, with the volume and units on a U-100 syringe at an example strength of 25 mg per mL; your vial’s label decides
DosemL at 25 mg/mLUnits (U-100)On the label
2.5 mg0.1 mL10 unitsStarting dose, for 4 weeks
5 mg0.2 mL20 unitsA maintenance dose
7.5 mg0.3 mL30 unitsA step up
10 mg0.4 mL40 unitsA maintenance dose
12.5 mg0.5 mL50 unitsA step up
15 mg0.6 mL60 unitsThe maximum, and a maintenance dose

The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units.

25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Read the strength on your own vial’s label; your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart. Or enter your own vial’s strength in the tirzepatide dosage calculator.

Loved by our members

Real stories from NexLife members about their care and service.

A selection of 5-star reviews from Trustpilot, quoted in full as written. Results vary from person to person, and weight loss isn’t guaranteed.

★★★★★TrustScore 4.8 out of 5 on Trustpilot407 reviews as of Nov. 15, 2026 · Read them all ↗

  • ★★★★★Read on Trustpilot ↗

    “Fast delivery and easy to get a hold of when needing to talk with someone!”

    Browneyes

  • ★★★★★Read on Trustpilot ↗

    “So happy with NexLife. Communication has been great, I’m recommending them to all my friends.”

    April

  • ★★★★★Read on Trustpilot ↗

    “Excellent visit. Dr. Kennah was very knowledgeable and helpful and answered all my questions.”

    Ethan B.

  • ★★★★★Read on Trustpilot ↗

    “That’s a real site with good prices and plans!”

    Estefany L.

  • ★★★★★Read on Trustpilot ↗

    “Affordable, quick and easy. They could not have made it a smoother less stressful experience.”

    Andisheh K.

  • ★★★★★Read on Trustpilot ↗

    “Great communication. Easy to work with. They work to set you up for success.”

    Anthony C.

  • ★★★★★Read on Trustpilot ↗

    “Easy and pricing not bad! Customer service was helpful in answering my questions.”

    Lyndy T.

  • ★★★★★Read on Trustpilot ↗

    “Good experience, great team”

    Mai S.

  • ★★★★★Read on Trustpilot ↗

    “Great communciation and was fast and reliable”

    Kiki

  • ★★★★★Read on Trustpilot ↗

    “Very happy so far”

    Tammy E.

  • ★★★★★Read on Trustpilot ↗

    “Fast service great communication!! Willing to work with you!”

    Bon

  • ★★★★★Read on Trustpilot ↗

    “Great service and excellent communication!”

    Gabrielle D.

Names are shortened for privacy. Reviews are members’ opinions, not medical advice.

What does NexLife cost?
One flat price at every dose.

No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†

Illustration of a compounded tirzepatide vialGIP + GLP-1

12-month plan $115/mo

Tirzepatide

Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan, $1,380 paid upfront; $129/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

Illustration of a compounded semaglutide vialGLP-1

12-month plan $95/mo

Semaglutide

Weekly GLP-1. Care, coaching and shipping included. On a 12-month plan, $1,140 paid upfront; $109/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

TrustScore 4.8 out of 5 on Trustpilot 407 reviews as of Nov. 15, 2026 · Read them all ↗

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms

The NexLife Price Match Guarantee†

Paying less elsewhere?
Keep your price. Upgrade your care.

Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.

  1. 1Send a receipt from the last 60 days
  2. 2A NexLife provider reviews your prescription
  3. 3Pay your matched price, at every dose
Switch and keep my price

Locked while your plan is activeSame price at every doseNo membership fee

†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.

Trulicity vs. tirzepatide: your questions

Fair questions about NexLife

Will my price go up with my dose?
No. You pay the same at every dose.
What if I’m not prescribed?
You aren’t charged for medication.
Can I cancel?
Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
Do I need insurance?
No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.

What’s the difference between Trulicity and tirzepatide?

Trulicity (dulaglutide) acts on GLP-1 alone and goes up to 4.5 mg; tirzepatide (Mounjaro) acts on GIP and GLP-1 and goes up to 15 mg. Both are Lilly’s weekly type 2 diabetes shots with a heart-risk use, Mounjaro’s since August 2026. For weight loss, both are off-label.

Does NexLife prescribe Trulicity or Mounjaro?

No. NexLife’s providers prescribe compounded tirzepatide and semaglutide only, for weight loss, and NexLife doesn’t bill insurance. Compounded tirzepatide isn’t FDA-approved, isn’t Mounjaro and isn’t a treatment for type 2 diabetes, so it doesn’t replace Trulicity or Mounjaro. Keep your diabetes care with the doctor who prescribes it.

How do you switch from Trulicity to Mounjaro?

With your provider, who decides when your last Trulicity dose is and when Mounjaro starts. Mounjaro’s label starts everyone at 2.5 mg a week, a starting dose only, and moves to 5 mg after 4 weeks; after that, it rises in 2.5 mg steps, at least 4 weeks apart, if blood sugar needs it. Don’t take both, and plan backup birth control if you take the pill.

Can you take Trulicity and Mounjaro together?

No. Both act on the GLP-1 receptor, and the Zepbound label, also tirzepatide, says not to combine tirzepatide with any GLP-1 medicine. If you’re moving from one to the other, your provider decides when one stops and the other starts.

How much do Trulicity and Mounjaro cost without insurance?

Mounjaro is $499 a month at LillyDirect, at every dose, for four pens (checked November 1, 2026). Lilly’s Trulicity savings page lists no self-pay price; Trulicity’s list price was $987.19 for four pens in January 2025, and pharmacies set cash prices. With commercial coverage, Lilly’s savings cards bring either to as little as $25 for up to 3 months.

Does Medicare cover Trulicity and Mounjaro?

For type 2 diabetes, your Part D plan should cover a GLP-1, Medicare.gov says, at your plan’s copay. Lilly’s savings cards don’t work with Medicare. Trulicity is on Medicare’s 2028 negotiation list: any agreed price takes effect January 1, 2028. Mounjaro isn’t on that list.

Is Trulicity or Zepbound better for weight loss?

Zepbound is FDA-approved for weight loss; Trulicity is off-label for it. In SURMOUNT-2 (2023), a 72-week trial in adults with type 2 diabetes, Zepbound 15 mg averaged 14.7% weight loss vs. 3.2% on placebo. On Trulicity 4.5 mg, weight fell 4.6 kg at 36 weeks (AWARD-11, 2021). These trials studied FDA-approved Zepbound and Trulicity; compounded tirzepatide wasn’t studied.

Does Mounjaro lower A1c more than Trulicity?

Yes, in SURPASS J-mono (2022): over 52 weeks, A1c fell 2.4% to 2.8% on tirzepatide 5 to 15 mg vs. 1.3% on Trulicity 0.75 mg, in Japanese adults. Trulicity’s top dose, 4.5 mg, lowered A1c 1.8% in AWARD-11 (2021). These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.

Does Trulicity or Mounjaro cause more weight loss?

Tirzepatide did, head to head: in SURPASS J-mono (2022), weight fell 5.8 to 10.7 kg on tirzepatide vs. 0.5 kg on Trulicity 0.75 mg over 52 weeks. For weight loss, both are off-label. These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.

Do Trulicity and Mounjaro both lower heart risk?

Yes: both labels include lowering the risk of heart attack, stroke and heart-related death, Mounjaro’s since August 2026. In SURPASS-CVOT (2025), tirzepatide was non-inferior to Trulicity 1.5 mg (hazard ratio 0.92), not superior. In REWIND (2019), that risk was 12% lower on Trulicity than on placebo. These trials studied FDA-approved Mounjaro and Trulicity; compounded tirzepatide wasn’t studied.

Does Mounjaro cause more side effects than Trulicity?

Head to head, nausea and loss of appetite were more common on tirzepatide. In SURPASS J-mono (2022), nausea hit 12% to 20% on tirzepatide vs. 8% on Trulicity 0.75 mg, and loss of appetite 13% to 22% vs. 4%. Both mostly cause stomach side effects, more often at higher doses. Compounded tirzepatide wasn’t studied in these trials.

Is the Trulicity savings card ending?

Yes. Lilly’s Trulicity savings card ends December 31, 2026. With commercial insurance that covers Trulicity, it can bring a fill to as little as $25 for up to 3 months, with up to $150 off a month and $1,950 a year. It isn’t for Medicare or other government plans.

Can children take Trulicity or Mounjaro?

Yes, for type 2 diabetes. Both are approved for blood sugar control in children 10 and older. In children, Trulicity goes up to 1.5 mg a week and Mounjaro up to 10 mg. Neither Trulicity nor Mounjaro is FDA-approved for weight loss, so using either for it is off-label.

Important safety information

Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation and stomach pain.

Read the full safety information

In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other GLP-1 medicines.

Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.

This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.

About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.

Who wrote and medically reviewed this page?

Adam Kennah, MDMedical Director, NexLife · Board-certified in emergency medicine (American Board of Emergency Medicine) · NPI 1144260043

Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.

NexLife Medical TeamWrites and updates NexLife’s guides

Labels, trial papers, Lilly’s savings terms and prices, and Medicare’s rules checked November 1, 2026.

  • How we checked. Label facts come from the Trulicity prescribing information (revised March 2026), the Mounjaro prescribing information (revised August 2026), which reports SURPASS-CVOT (The New England Journal of Medicine, 2025), and the Zepbound label, whose Study 2 is SURMOUNT-2 (The Lancet, 2023). SURPASS J-mono comes from its published paper (The Lancet Diabetes & Endocrinology 2022;10:623-633), AWARD-11 from its abstract (Diabetes Care 2021;44:765-773) and REWIND’s results from the Trulicity label (The Lancet, 2019). Lilly’s savings terms and Trulicity price disclosure, LillyDirect, Medicare.gov and CMS were read on November 1, 2026; compounded prices come from our GLP-1 price index, checked November 1, 2026. We don’t forecast prices. Trulicity, Mounjaro, Zepbound, KwikPen and LillyDirect are trademarks of Eli Lilly and Company, and Saxenda and Wegovy of Novo Nordisk. NexLife isn’t affiliated with either.
  • Every fact, sourced. Each price and rule links to the page it comes from.
  • How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
  • Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
  • How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves

Paying less elsewhere? We match it.†

Thinking about tirzepatide? Start with a 3-minute check.

A licensed provider reviews your health history and every medicine you take, and decides if compounded tirzepatide is right for you: $115 a month on the 12-month plan, or $129 month to month, at every dose.

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified

Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.

  1. 1
    Tell us about you

    Start online with your health history.

  2. 2
    A licensed provider decides

    Online, following your state’s rules. You’re prescribed only if treatment is right for you.

  3. 3
    We ship it, then stay with you

    Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.

Sources

  1. Trulicity (dulaglutide) prescribing information, Eli Lilly, revised March 2026. Read November 1, 2026.
  2. Mounjaro (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 15, 2026.
  3. Zepbound (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 15, 2026.
  4. SURPASS J-mono: Inagaki N, et al. Tirzepatide monotherapy vs. dulaglutide in Japanese patients with type 2 diabetes. Lancet Diabetes Endocrinol 2022;10:623-633. Paper read October 25, 2026.
  5. AWARD-11: Frias JP, et al. Dulaglutide 3.0 mg and 4.5 mg vs. 1.5 mg in metformin-treated type 2 diabetes. Diabetes Care 2021;44:765-773. Abstract read October 25, 2026.
  6. SURPASS-CVOT: Nicholls SJ, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med 2025;393:2409-2420. Citation as given by the American College of Cardiology, read October 25, 2026; results as stated in Mounjaro’s label.
  7. REWIND: Dulaglutide and cardiovascular outcomes in type 2 diabetes. The Lancet 2019;394:121-130. Citation checked October 25, 2026; results as stated in Trulicity’s label.
  8. SURMOUNT-2: Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes. The Lancet, 2023 (American College of Cardiology trial summary). Read November 1, 2026; results as stated in Zepbound’s label (Study 2).
  9. Lilly: Trulicity Savings Card and terms. Checked November 1, 2026.
  10. Lilly: Trulicity price disclosure, wholesale acquisition cost (PP-LU-US-1366, January 2025). Read November 1, 2026; price as of January 2, 2025.
  11. Lilly: Mounjaro Savings Card. Checked November 1, 2026.
  12. LillyDirect: Mounjaro self-pay price. Checked November 15, 2026.
  13. LillyDirect: Zepbound self-pay prices. Checked November 15, 2026.
  14. Medicare.gov: Weight loss drugs (who the Medicare GLP-1 Bridge covers). Read November 15, 2026.
  15. CMS: Medicare drug price negotiation, selected drugs for 2028 (announced January 27, 2026). Read November 1, 2026.
  16. NexLife: GLP-1 price index. Compounded prices checked November 1, 2026.
  17. NexLife: pricing, every plan.
  18. Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, web version. Revised August 2026; section 1 read November 15, 2026.
  19. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026; read November 15, 2026.